SCM
CMPX icon

Silverarc Capital Management’s Compass Therapeutics CMPX Stock Holding History

Silverarc Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-859,049
Closed -$4.54M – 79
2026
Q1 		$4.54M Sell
859,049
-192,294
-18% -$1.11M 0.46% 46
2025
Q4 		$5.65M Sell
1,051,343
-1,782,645
-63% -$8.23M 0.78% 35
2025
Q3 		$9.92M Buy
2,833,988
+1,584,207
+127% +$5M 1.34% 24
2025
Q2 		$3.25M Buy
1,249,781
+374,912
+43% +$773K 0.6% 39
2025
Q1 		$1.66M Buy
+874,869
New +$2.33M 0.34% 53
2023
Q1 		– Sell
-268,307
Closed -$1.35M – 84
2022
Q4 		$1.35M Buy
268,307
+6,217
+2% +$24.8K 0.39% 63
2022
Q3 		$598K Buy
+262,090
New +$726K 0.2% 67

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Silverarc Capital Management's CMPX Position: Q2 2026 in Review

Silverarc Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 859,049 shares — an estimated $4.54M sold.

Silverarc Capital Management first reported a position in CMPX in Q3 2022 and held it in 7 quarters. The position peaked at $9.92M in Q3 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Silverarc Capital Management reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 859,049 Compass Therapeutics shares in Q2 2026, an estimated $4.54M.
  • Silverarc Capital Management first reported a position in Compass Therapeutics in Q3 2022 and held it in 7 quarters.
  • Silverarc Capital Management's Compass Therapeutics position peaked at $9.92M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.